- cafead Aug 09, 2024 at 11:32: AM
via Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged.
The company’s CAR-T therapy Carvykti, partnered with Johnson & Johnson, is starting a key launch in second-line multiple myeloma, as the two partners are busy expanding capacity at multiple manufacturing sites simultaneously.
article source
The company’s CAR-T therapy Carvykti, partnered with Johnson & Johnson, is starting a key launch in second-line multiple myeloma, as the two partners are busy expanding capacity at multiple manufacturing sites simultaneously.
article source